Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in SLE
NCT06570434Phase 2Withdrawn
- Sponsor
- Tenet Medicines
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of budoprutug in systemic lupus erythematosus (SLE), sponsored by Tenet Medicines. Planned start Jan 2025; status: withdrawn.
02
Drugs
budoprutug
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06570434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570434.